Lactate dehydrogenase test market information: by type (LD1, LD2, LD3, LD4, LD5) by indications (cerebrovascular diseases, liver diseases, blood disorders, others) by equipment (instruments, consumables, others) end users - Global Forecast till 2027
Considering all these factors the market for lactate dehydrogenase test is expected to reach $ 6.4 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 8.8 % during 2017-2023.
Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/3884
• LDH-1 is found primarily in heart muscle and red blood cells
• LDH-2 is found primarily in white blood cells
• LDH-3 is found primarily in the lungs
• LDH-4 is found primarily in the kidney, placenta, and pancreas
• LDH-5 is found primarily in the liver and skeletal muscle
Thus higher values of any particular enzyme denotes diseases of different organs. Thus, lactate dehydrogenase is used as an indicator to diseases such as cerebrovascular diseases, liver diseases, blood disorders, muscle dystrophy, fatigue, necrosis, infections, substance abuse etc. The development of high sensitivity and selective reagents and instruments has boosted the growth of the market as it increases the reliability of the test. However the development of substitute tests which are more sensitive for particular disease condition has threatened the future market.
The growth of substance abuse and workplace rules to check the use of substance abuse has led to increase in testing services which will add to the growth of the lactate dehydrogenase test market.
Key players of Global Lactate dehydrogenase test Market:
LifeSpan BioSciences,
Aviva Systems Biology,
Accurex Biomedical Pvt. Ltd.,
Thermo Fisher Scientific,
Bioo Scientific Corporation,
Quest Diagnostics,
Abcam plc.,
Randox Laboratories Ltd.,
Sigma-Aldrich Co. LLC.,
Merck KGaA
others.
Lactate dehydrogenase test market is estimated to be led by the developing regions of Asia Pacific which is further estimated to be dominated by China and India. Countries of the developing world such as Indonesia, Cambodia, China, and India will land a lion’s share for the market for lactate dehydrogenase test in the Asia Pacific. The presence of large populations with unmet needs and the growing screening rates is the strongest driver of growth in these markets. Thus, there is larger potential to grow in the developing regions due to less competition. The growing number of lactate screening for diseases and workplace substance abuse screening is the strongest factor responsible for the growth of the Asia Pacific market.
Segmentation:
The global lactate dehydrogenase test market is segmented
Segmentation on the basis of type, indications, equipment, and end users. Based on type, the market has been segmented as lactate dehydrogenase 1 (LD1), lactate dehydrogenase 2 (LD2), lactate dehydrogenase 3 (LD3), lactate dehydrogenase 4 (LD4), and lactate dehydrogenase 5 (LD5). Based on the indications,the market has been segmented as cerebrovascular diseases, liver diseases, blood disorders, muscle dystrophy and fatigue, necrosis, infections, substance abuse, and others. Based on the equipment, the market has been segmented as instruments (spectroscope, centrifuge, others), consumables and others. Based on the end users, the market has been segmented as hospitals and clinics, diagnostic laboratories, academic and research and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/lactate-dehydrogenase-test-market-3884
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Comentarios